Cingulate Inc. 8-K Summary
Business Context and Reporting Period
Cingulate Inc. (CING), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on February 2, 2024. The report details a definitive agreement entered into on February 2, 2024, for a best efforts public offering of equity securities. The offering officially closed on February 6, 2024.
Key Financial Metrics and Transaction Details
The Company sold an aggregate of 1,375,000 shares of Common Stock and pre-funded warrants to purchase up to 2,375,000 shares of Common Stock. Each unit included accompanying Series A and Series B warrants.
- Offering Price: $2.00 per share of Common Stock; $1.9999 per Pre-Funded Warrant.
- Net Proceeds: Approximately $6.5 million after deducting placement agent fees and offering expenses.
- Placement Agent Fees: 7.8% cash fee on gross proceeds, plus $100,000 for legal/expenses, $50,000 expense allowance, and $15,950 clearing expenses.
- Placement Agent Warrants: 150,000 warrants issued to H.C. Wainwright & Co., LLC (4.0% of units sold) with an exercise price of $2.50, expiring February 2, 2029.
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period, as this is a transactional report rather than a periodic financial statement.
Material Changes and Covenants
The primary material change is the capital raise and the associated dilution from the issuance of shares and warrants. The Company agreed to the following covenants in the Purchase Agreement:
- 90-Day Lock-Up: No issuance of Common Stock or convertible securities for 90 days post-closing, subject to exceptions.
- Variable Rate Restriction: No variable rate transactions for one year post-closing, subject to exceptions.
- Beneficial Ownership Limit: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% or 9.99% of outstanding shares.
Outlook, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to use the net proceeds for continued research and development and commercialization of its lead asset, CTx-1301, as well as for working capital, capital expenditures, and general corporate purposes.
Risks and Contingencies: The filing notes that the description of the agreements is qualified by reference to the full text of the exhibits. The Company is subject to customary representations, warranties, and indemnification obligations. The text does not provide specific forward-looking guidance on revenue or earnings.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the exercise terms and expiration dates for Series A (5 years) and Series B (2 years) warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and conditions.
- Monitor the progress of CTx-1301 development as the primary use of the raised capital.
- Check subsequent filings for any waivers to the 90-day lock-up or variable rate transaction restrictions.